Showing 1551-1560 of 2050 results for "".
- CooperVision Shares Latest Contact Lens Research Results in Paper and Poster Presentations at Academy 2019https://modernod.com/news/coopervision-shares-latest-contact-lens-research-results-in-paper-and-poster-presentations-at-academy-2019/2477027/CooperVision clinicians and research partners are among the hundreds of presenters lined up to report their scientific advancements this week at Academy 2019 in Orlando. The latest company and company-sponsored research will be summarized in a series of papers and posters that encompass the compa
- GenSight Biologics Reports Evidence of GS010 DNA Transfer to Contralateral Eye of Primates Unilaterally Injected With GS010 Gene Therapyhttps://modernod.com/news/gensight-biologics-reports-evidence-of-gs010-dna-transfer-to-contralateral-eye-of-primates-unilaterally-injected-with-gs010-gene-therapy/2476960/GenSight Biologics reported positive proof of GS010 DNA transfer from one eye to the other eye following unilateral intravitreal injection of primates. In a nonclinical study to investigate the local biodistribution of GS010, tissue samples from the non-injected eye of monkeys that had been unila
- MIGS Devices Continue to Expand Use of Glaucoma Surgeryhttps://modernod.com/news/migs-devices-continue-to-expand-use-of-glaucoma-surgery/2476811/Minimally invasive glaucoma surgery (MIGS) stents account for nearly half of all glaucoma surgical device revenue in 2019, according to a Market Scope report. Market penetration of these stents over the past 5 years has been impressive, but the voluntary recall of the Alcon CyPass in 2018
- Vision Source Wins $2 Million Contract for Achievements in Value-Based Carehttps://modernod.com/news/vision-source-wins-2-million-contract-for-achievements-in-value-based-care/2476745/Southern New England Practice Transformation Network (SNE-PTN) will be awarding over 1,100 select Vision Source member practices achievement payments of up to $2,500 per practice for their performance in the transformation towards value-based care in 2019. Vision Source member practices co
- Johnson & Johnson Vision Showcases the Rising Burden of Myopia, New Contact Lens and Surgical Technologies at ARVOhttps://modernod.com/news/johnson-johnson-vision-showcases-the-rising-burden-of-myopia-new-contact-lens-and-surgical-technologies-at-arvo/2476549/Johnson & Johnson Vision showcased new research abstracts covering topics across a range of eye health needs at the Association for Research in Vision and Ophthalmology annual meeting (ARVO) in Vancouver, Canada, April 28-May 2, 2019. Presentations included the first predictive model for dire
- Roche Further Extends Tender Offer for Spark Therapeutics as FTC Review Continueshttps://modernod.com/news/roche-further-extends-tender-offer-for-spark-therapeutics-as-ftc-review-continues/2476508/Roche said Friday that it is extending its offer period related to the proposed acquisition of Spark Therapeutics for a second time to give the US Federal Trade Commission (FTC) more time to review the deal, according to FirstWord. Roche noted that the FTC’s “review of the transaction
- Retreatment With A Single TearCare Treatment Continues To Provide Relief For Patients With Dry Eye Diseasehttps://modernod.com/news/retreatment-with-a-single-tearcare-treatment-continues-to-provide-relief-for-patients-with-dry-eye-disease/2476302/A new, single center, prospective clinical study published in the January issue of Clinical Ophthalmology provides preliminary evidence that retreatment with the Sight Sciences TearCare System is a safe and effective treatment for dry eye disease, according to a company news release. The
- Galimedix Therapeutics Presents Data for Investigational Eyedrops Containing GAL-101https://modernod.com/news/galimedix-therapeutics-presents-data-for-investigational-eyedrops-containing-gal-101/2476320/Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, presented an overview of data disclosed to date on its novel, first-in-class, investigational compound GAL-101, which in animal models caused sustained prevention of misfolded amyloid beta mol
- Controlled Trial Shows Promise of Donated Stem Cells in Restoring Visionhttps://modernod.com/news/controlled-trial-shows-promise-of-donated-stem-cells-in-restoring-vision/2476345/A study in STEM CELLS Translational Medicine provides a deeper and clearer understanding of how patients suffering vision loss in both eyes due to limbal stem cell deficiency (LSCD) might benefit from a stem cell transplant using donated cells. This is the first ra
- The Number of Optometric Practices Offering neurolens Contoured Prism Lenses More Than Quadrupled in 2018https://modernod.com/news/the-number-of-optometric-practices-offering-neurolens-contoured-prism-lenses-more-than-quadrupled-in-2018/2479617/Costa Mesa, California-based neurolens announced that adoption of their prescription lenses has grown among US optometric (OD) practices and by year end, 31 states will carry the company’s neurolenses and the neurolens measurement device. neurolenses are the first and only prescripti